爱尔兰爵士制药的去纤苷注射方法

(Defibrotide) is a mixture of single-stranded oligonucleotides decomposed from genomic DNA from calf lungs or pig intestinal mucosa. The oligonucleotide chain lengths of this drug vary, and the relative molecular mass ranges from 15×10³ to 30×10³. Its purine to pyrimidine ratio is greater than 0.85. The mechanism of action of defibrotide is complex and is not yet fully understood. Preclinical studies have confirmed that the drug has anti-thrombotic, fibrinolytic, anti-ischemic and anti-infective effects in vivo and in vitro. In order to ensure that the efficacy of the drug is fully exerted, it is very important for patients to understand and master the correct usage and dosage of defibrotide. So, how to use defibrinoside?

Defibrinoside from Sir Irish Pharmaceuticals can be administered via intravenous injection and oral administration. Intravenous administration can quickly reach the maximum blood concentration Cmax, and oral administration can reach Cmax 30 minutes later. In view of factors such as hydrolytic inactivation of digestive tract nucleases, intestinal absorption efficiency of defibrinoside, and liver first-pass effect, the oral bioavailability is only 58~71%. The half-life of defibrinated sodium for injection is about 10 to 30 minutes, while the elimination of defibrinated sodium for oral administration takes several hours and is mainly excreted through urine and feces. The advantage of oral administration is that defibrinated sodium can exert its effect slowly and continuously. 

In general, the recommended dose of defibrotide sodium for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Give Defitelio for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD.

Jazz Pharmaceuticals was founded in 2003 and is headquartered in Dublin, Ireland, with 885 full-time employees. It is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of pharmaceutical products. Its drugs are quite effective in treating hepatic veno-occlusive disease, and patients can use them with confidence.

Recommended hot articles: /newsDetail/90895.html